Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Will The Rising Tide Of Rx Omega-3s Float The Fish Oil Supplement Market?

This article was originally published in The Tan Sheet

Executive Summary

Omega-3 fish oils, once exclusive to the realm of dietary supplements, increasingly are swimming upstream into prescription drugs – a trend with both positive and negative implications for supplements.

You may also be interested in...



Doctors Often Recommend Omega-3 Supplements For High Cholesterol – Survey

A survey of doctors and pharmacists reports 83% of their patients with abnormally high cholesterol express interest in using omega-3 supplements. But the survey sponsored by Rx omega-3 firm Amarin also raises questions about health care professionals’ knowledge of FDA regulation of supplement products.

Doctors Often Recommend Omega-3 Supplements For High Cholesterol – Survey

A survey of doctors and pharmacists reports 83% of their patients with abnormally high cholesterol express interest in using omega-3 supplements. But the survey sponsored by Rx omega-3 firm Amarin also raises questions about health care professionals’ knowledge of FDA regulation of supplement products.

Pronutria Gains $12.5 Million Funding For Protein Product Trials

The start-up developer of medical foods and supplements is conducting clinical trials on two candidates to stave off muscle loss in elderly people. The firm soon may begin development of therapeutic product candidates with a separate business unit.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS104823

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel